BCL2 apoptosis regulator

Where the papers sit

38 papers from the last 6 months study BCL2 apoptosis regulator directly · updated from PubMed 12 Oct 2026

• Experimental Anticancer Apoptosis

  Natural products and synthetic compounds are being screened for cytotoxicity, apoptosis, and cell-cycle arrest across cancer models. Recurrent endpoints include MTT-based viability, IC50, CDK4/6 and BCL-2 pathway changes, with ROS and metabolic profiles adding mechanistic context. A smaller translational strand tests BCL-2 targeting in castration-resistant prostate cancer and combinations such as clomipramine with sorafenib in hepatocellular carcinoma. The evidence remains heterogeneous, leaving the clinically useful compounds and predictive biomarkers unresolved.

  10 papers · 26.3%

• Oxidative Stress and Apoptosis

  Oxidative stress and mitochondrial apoptosis are being treated as shared mechanisms across seizures, ischemic stroke, toxic testicular injury, cardiac valve disease, alopecia, and cancer. Most studies track BCL2/BAX, CASP3, ROS, inflammatory cytokines, and tissue histology as evidence of pathway modulation. Natural products, photodynamic therapy, engineered exosomes, and mitochondrial protective peptides all aim to shift the balance toward cell survival or tumor cell death. The breadth supports mechanistic convergence, but efficacy remains largely preclinical and context-dependent.

  10 papers · 26.3%

• Cancer Apoptosis and Invasion

  Apoptosis, oxidative stress, and invasive behavior recur across studies of breast and other solid tumors. Breast cancer work emphasizes berberine, plant extracts, and organosulfur compounds that alter ROS, mitophagy, MMP-9, adhesion, migration, and apoptotic markers. Other papers examine BCL-2 variants, exosomal miRNAs, wound microenvironments, and treatment-associated mutations, extending the theme beyond one tumor type. The shared direction is mechanistic target discovery rather than a settled therapeutic strategy, with clinical relevance still uncertain.

  9 papers · 23.7%

• Venetoclax in Acute Leukemia

  Venetoclax research is moving toward biomarker-guided combinations that eradicate leukemia stem cells rather than relying on BCL-2 inhibition alone. Studies pair it with gilteritinib, inobrodib, PI3Kδ inhibition, or cytotoxic chemotherapy and relate response to genomic subtype. Retrospective work highlights febrile neutropenia as a concentration-linked safety concern. Questions remain about resistance, optimal scheduling, and how broadly findings extend beyond AML and T-ALL.

  7 papers · 18.4%

• Antioxidant Sperm Cryopreservation

  Nanoparticle-loaded antioxidants are being used to protect sperm during freeze-thaw storage. Lutein- or mangiferin-loaded chitosan formulations recur, with outcomes centered on progressive motility, total antioxidant capacity, and apoptotic injury. The work links improved post-thaw quality to reduced oxidative and mitochondrial damage in ram and buffalo semen. Comparative dosing, extender composition, and reproductive outcomes remain open.

  2 papers · 5.3%